Herceptin News and Research

RSS

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry.

19 Oct 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

Scientists identify gene that could predict breast cancer patients' response to tamoxifen

Scientists have identified a gene which could help predict whether a breast cancer patient will respond to taking tamoxifen. The study, published in the British Journal of Cancer today (Wednesday), showed a potential link between the activity of a gene called BCAR4 and the likelihood that a breast cancer tumour will not respond to tamoxifen - widely used to treat women with breast cancer.

13 Oct 2010

Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium

Array BioPharma Inc. today announced positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer.

4 Oct 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

Regular consumption of watercress can prevent breast cancer: Research

Watercress, the super food, is now watercress the breast cancer preventive according to a study released September 20, 2010 in The British Journal of Nutrition conducted by the Cancer Research Centre at the School of Medicine, Southampton General Hospital in the United Kingdom.

21 Sep 2010

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Scientists discover over-expression of C35 gene in HER2 positive tumours

UK scientists have discovered that a gene called C35 can work together with other cancer-promoting genes to drive the growth and invasion of breast cancer cells in the lab.

9 Sep 2010

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma, Inc. today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase.

2 Sep 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

Genentech asserts SPC non-infringement of products in Europe, seeks response from PDL

PDL BioPharma, Inc. announced today it has received a facsimile letter from Genentech asserting that Avastin, Herceptin, Lucentis and Xolair (the Genentech Products) do not infringe supplementary protection certificates granted by various countries in Europe to PDL and is seeking a response from PDL to these assertions.

16 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

Scientists discover that C35 gene becomes overactive in HER2 positive tumours

UK scientists have discovered that a gene called C35 can work together with other cancer-promoting genes to drive the growth and invasion of breast cancer cells in the lab.

16 Jul 2010

New study on impact of bortezomib on mantle cell lymphoma

A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.

13 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.

22 Jun 2010